Khiron Life Sciences completes acquisition of ILANS

1 minute read
13 December 2018

On December 13, 2018, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC) announced that it had completed its previously announced acquisition of the Latin American Institute of Neurology and the Nervous System ("ILANS"). ILANS is one of the most respected, fastest growing and largest health service network providers in Colombia and Latin America.

Khiron, with core operations in Colombia, is positioned to be the dominant integrated medical cannabis company in Latin America. In May 2018, Khiron listed on the TSX Venture Exchange, becoming the first Colombian based medical cannabis company to trade on any exchange globally.

Gowling WLG advised Khiron with respect to this acquisition with a team that included Peter Simeon, Marek Lorenc and Josh Rosen.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.